IQVIA (NYSE:IQV) Receives Outperform Rating from Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of IQVIA (NYSE:IQV - Free Report) in a research note released on Monday,Benzinga reports. The brokerage currently has a $270.00 price objective on the medical research company's stock.

Several other research analysts have also recently weighed in on the company. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Morgan Stanley cut their price target on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. TD Cowen decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. Leerink Partners reiterated an "outperform" rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus price target of $251.67.

IQVIA Stock Down 0.5 %

Shares of NYSE IQV traded down $1.06 during trading on Monday, hitting $196.76. The stock had a trading volume of 497,502 shares, compared to its average volume of 1,379,656. The firm has a fifty day moving average of $200.66 and a two-hundred day moving average of $218.67. The company has a market capitalization of $35.71 billion, a PE ratio of 26.23, a PEG ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts forecast that IQVIA will post 10.81 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John G. Danhakl purchased 1,275 shares of the business's stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.60% of the company's stock.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently made changes to their positions in the stock. Norges Bank bought a new position in IQVIA in the fourth quarter valued at $336,041,000. Raymond James Financial Inc. purchased a new position in shares of IQVIA in the 4th quarter worth about $236,120,000. American Century Companies Inc. increased its position in shares of IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after purchasing an additional 905,960 shares during the last quarter. Invesco Ltd. raised its holdings in shares of IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, FMR LLC lifted its position in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after buying an additional 804,963 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.